| Biomarker ID | 454 |
| PMID | 19773444 |
| Year | 2009 |
| Biomarker | MIC-1 (Macrophage inhibitory cytokine 1); A1BG a-1B-glycoprotein1 precursor; VTNC (Vitronectin precursor); RNPEP (Arginyl aminopeptidase); FETUA (Fetuin A) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Upregulated in Docetaxel- resistant PC3-Rx cells [(MIC-1 Macrophage inhibitory cytokine 1 (2.4 fold); A1BG a-1B-glycoprotein1 precursor (1.9 fold) ; VTNC Vitronectin precursor (1.7 fold); RNPEP Arginyl aminopeptidase (1.6 fold); FETUA Fetuin A (1.6 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-TAp63 pathway, p73 transcription factor network,p53 signaling pathway,BDNF signaling pathway |
| Experiment | Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells |
| Type of Biomarker | Potential Predictive |
| Cohort | Docetaxel-sensitive PC3 cells and Docetaxel resistant PC3-Rx cells developed by Docetaxel dose escalation were selected for this analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | iTRAQ-mass spectrometry |
| Clinical | Yes |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Human patient cohort |
| Technical Name | GDF15 |